Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic IP of Dr. Thomas Arendt From University of Leipzig
August 01 2014 - 8:00AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to endoplasmic reticulum
stress, cell cycle dysregulation, neurodegeneration and apoptosis,
today announced that it has acquired an exclusive option to license
the intellectual property surrounding the therapeutic concepts of
Dr. Thomas Arendt from the University of Leipzig that were
presented at the 3rd Alzheimer's focused Coalition for Concussion
Treatment Summit. Under the terms of the agreement, the Company and
the University of Leipzig will have 12 months to negotiate a
definitive license agreement, and the Company will work with Dr.
Arendt to establish a Sponsored Research Agreement to outline the
advancement of the therapeutic strategies into human clinical
development.
"We are extremely pleased to enter into this agreement that
further positions Amarantus within the cell cycle dysregulation
field in Alzheimer's disease," said Gerald E. Commissiong,
President & CEO of Amarantus. "We believe new concepts and
ideas are required to make progress in treating this devastating
disorder, and we believe Dr. Arendt's pioneering work that led to
LymPro also has therapeutic applications. We look forward to
working with the University to execute definitive agreements."
Dr. Arendt has filed international patent applications on the
concepts of modulating the expression of P16 in the brains of
patients of Alzheimer's disease using gene therapy. P16 is a cell
cycle protein that assists in maintaining and nurturing synaptic
connections that is hypothesized to be at the root of Alzheimer's
pathology. The Company is currently developing an Alzheimer's blood
diagnostic LymPro Test® capable of identifying cell cycle
dysregulation by harvesting peripheral blood lymphocytes. This
option agreement opens the possibility of a targeted therapeutic on
those Alzheimer's patients that have tested positive for
LymPro.
About Alzheimer's disease
It is estimated that over 5.4 million people in the United
States suffer from Alzheimer's disease and over 500,000 patients
are diagnosed annually, with nearly one in eight older Americans
affected by the disease. Alzheimer's is the third leading cause of
death in the United States. The estimated cost of unpaid care in
the United States is estimated at over $210 billion annually and
the total payments for care are estimated at over $200 billion
annually, including $140 billion in cost to Medicare and Medicaid.
It is estimated that the cost to the United States will exceed $1.4
trillion by 2050.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small
molecule indicated for Parkinson's Levodopa induced dyskinesia and
Adult ADHD. AMBS has an exclusive worldwide license to the
Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's
disease and owns the intellectual property rights to a therapeutic
protein known as Mesencephalic-Astrocyte-derived Neurotrophic
Factor ("MANF") and is developing MANF-based products as treatments
for brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements." These forward-looking statements
generally are identified by the words believes," project,"
expects," anticipates," estimates," intends," strategy," plan,"
may," will," would," will be," will continue," will likely result,"
and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and
uncertainties which may cause actual results to differ materially
from the forward-looking statements. Our ability to predict results
or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on
our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest
rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in
evaluating forward-looking statements and undue reliance should not
be placed on such statements.
CONTACT: Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024